Allspring Global Investments Holdings LLC Boosts Position in Zymeworks Inc. (NYSE:ZYME)

Allspring Global Investments Holdings LLC increased its stake in Zymeworks Inc. (NYSE:ZYME) by 20.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 227,625 shares of the company’s stock after acquiring an additional 38,181 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Zymeworks were worth $2,365,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ZYME. Wellington Management Group LLP increased its position in Zymeworks by 177.9% during the 3rd quarter. Wellington Management Group LLP now owns 156,682 shares of the company’s stock valued at $993,000 after purchasing an additional 100,304 shares during the period. Acadian Asset Management LLC increased its position in Zymeworks by 742.4% during the 3rd quarter. Acadian Asset Management LLC now owns 825,988 shares of the company’s stock valued at $5,233,000 after purchasing an additional 727,934 shares during the period. Ritholtz Wealth Management purchased a new position in Zymeworks during the 4th quarter valued at about $329,000. Swiss National Bank increased its position in Zymeworks by 11.2% during the 3rd quarter. Swiss National Bank now owns 77,600 shares of the company’s stock valued at $492,000 after purchasing an additional 7,800 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Zymeworks during the 3rd quarter valued at about $158,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Zymeworks Stock Performance

NYSE ZYME opened at $8.85 on Monday. The company’s 50-day simple moving average is $10.76 and its two-hundred day simple moving average is $9.59. Zymeworks Inc. has a one year low of $6.01 and a one year high of $13.14. The company has a market capitalization of $624.54 million, a price-to-earnings ratio of -5.09 and a beta of 1.14.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.19. Zymeworks had a negative net margin of 156.12% and a negative return on equity of 26.20%. The firm had revenue of $16.93 million for the quarter, compared to the consensus estimate of $18.32 million. Equities analysts expect that Zymeworks Inc. will post -1.04 earnings per share for the current fiscal year.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.